<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172987</url>
  </required_header>
  <id_info>
    <org_study_id>17103</org_study_id>
    <secondary_id>I8F-MC-GPGR</secondary_id>
    <nct_id>NCT04172987</nct_id>
  </id_info>
  <brief_title>A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants</brief_title>
  <official_title>Effect of Tirzepatide on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at how the body processes the commonly prescribed birth&#xD;
      control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and&#xD;
      the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side&#xD;
      effects that may occur will also be collected.&#xD;
&#xD;
      Screening is required within 28 days prior to the start of the study. For each participant,&#xD;
      the study will last about 20 weeks, including screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2020</start_date>
  <completion_date type="Actual">February 9, 2021</completion_date>
  <primary_completion_date type="Actual">February 9, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol (EE)</measure>
    <time_frame>Periods 1 and 2 on Day 21: Pre-dose through 24 hours post-dose</time_frame>
    <description>PK: AUC(0-tau) of EE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of EE</measure>
    <time_frame>Periods 1 and 2 on Day 21: Pre-dose through 48 hours post-dose</time_frame>
    <description>PK: Cmax of EE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: AUC(0-tau) of Norelgestromin (NGMN)</measure>
    <time_frame>Periods 1 and 2 on Day 21: Pre-dose through 24 hours post-dose</time_frame>
    <description>PK: AUC(0-tau) of NGMN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Cmax of Norelgestromin (NGMN)</measure>
    <time_frame>Periods 1 and 2 on Day 21: Pre-dose through 48 hours post-dose</time_frame>
    <description>PK: Cmax of NGMN</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ethinyl Estradiol + Norgestimate (EE/NGM) Alone (Period 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EE and NGM (active tablets) administered orally for 21 days, then non-active tablets administered orally for 7 days. (1 course of oral contraceptive = 28 days.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EE/NGM + Tirzepatide (Period 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EE and NGM (active tablets) administered orally for 21 days, then non-active tablets administered orally for 7 days. (1 course of oral contraceptive = 28 days.)&#xD;
Tirzepatide administered by subcutaneous injection (SC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>EE/NGM + Tirzepatide (Period 2)</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE/NGM</intervention_name>
    <description>Combination oral contraceptive administered orally</description>
    <arm_group_label>EE/NGM + Tirzepatide (Period 2)</arm_group_label>
    <arm_group_label>Ethinyl Estradiol + Norgestimate (EE/NGM) Alone (Period 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overtly healthy females as determined by medical history, physical examination, and&#xD;
             other screening procedures&#xD;
&#xD;
          -  Have a body mass index (BMI) equal to or above 18.5 kilograms per meter squared&#xD;
             (kg/mÂ²), at screening&#xD;
&#xD;
          -  Are not intending to start a family within 2 months after the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have known allergies to either tirzepatide or ethinylestradiol or norgestimate or&#xD;
             related compounds&#xD;
&#xD;
          -  Have a medical condition or medical history that precludes the taking of combined oral&#xD;
             contraceptives&#xD;
&#xD;
          -  Have a history or presence of pancreatitis (history of chronic pancreatitis or&#xD;
             idiopathic acute pancreatitis), elevation in serum amylase or lipase or&#xD;
             gastrointestinal (GI) disorder (eg, relevant esophageal reflux or gall bladder&#xD;
             disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery,&#xD;
             pyloric stenosis, with the exception of appendectomy) or could be aggravated by&#xD;
             glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors&#xD;
&#xD;
          -  Have used hormonal implants or received hormonal injections in the past 12 months&#xD;
&#xD;
          -  Unwilling to comply with smoking restrictions during the study&#xD;
&#xD;
          -  Is a known user of drugs of abuse&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirzepatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

